MichaelEOhlMD
Infectious Disease • Iowa City, IAAssistant Professor, Internal Medicine, University of Iowa College of Medicine
Dr. Ohl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 Hawkins Dr
Iowa City, IA 52242Phone+1 319-356-7740Fax+1 319-384-7208
Education & Training
University of Missouri-ColumbiaResidency, Family Medicine, 2003 - 2004
University of WashingtonFellowship, Infectious Disease, 1999 - 2002
University of California (San Francisco)Residency, Internal Medicine, 1996 - 1999
Washington University in St. Louis School of MedicineClass of 1996
Certifications & Licensure
CA State Medical License 1998 - Present
IA State Medical License 2006 - 2026
WA State Medical License 1999 - 2004- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
- American Board of Preventive Medicine Addiction Medicine
Clinical Trials
- Rural PrEP Delivery Start of enrollment: 2018 Feb 01
Publications & Presentations
PubMed
- Another step forward in implementing long-acting PrEP.Quanhathai Kaewpoowat, Michael E Ohl
The Lancet. HIV. 2024-11-01 - 2 citationsSexually Transmitted Infection Testing in the National Veterans Health Administration Patient Cohort During the Coronavirus Disease 2019 Pandemic.Lauren A Beste, Shimrit Keddem, Joleen Borgerding, Elliott Lowy, Carolyn Gardella
Open Forum Infectious Diseases. 2022-12-01 - 5 citationsEffectiveness and Optimal Duration of Adjunctive Rifampin Treatment in the Management ofProsthetic Joint Infections After Debridement, Antibiotics, and Implant Retention.Hiroyuki Suzuki, Michihiko Goto, Rajeshwari Nair, Daniel J Livorsi, Poorani Sekar
Open Forum Infectious Diseases. 2022-09-01
Press Mentions
University of Iowa Led Observational Study Reveals Remdesivir Can Lengthen Hospital Stay & Not Contribute to SurvivalJuly 21st, 2021- Remdesivir Treatment Plan Kept COVID-19 Patients Hospitalized Longer, University of Iowa Research ShowsJuly 21st, 2021
- Remdesivir Treatment Period for COVID-19 Patients Kept Hospital Beds Full While They Were ScarceJuly 20th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
